Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Asia Pacific Lancet and Pen Needles Market size at USD 1,416.30 million in 2023. During the ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares soared over 14% ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

Novo Nordisk A/S has moved -53.6% over the last year, and the S&P 500 logged a change of 5.4% NVO has an average analyst ...